Now showing items 1-1 of 1

    • Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer. 

      Cato, L; Neeb, A; Sharp, A; Buzón, V; Ficarro, SB; Yang, L; Muhle-Goll, C; Kuznik, NC; Riisnaes, R; Nava Rodrigues, D; Armant, O; Gourain, V; Adelmant, G; Ntim, EA; Westerling, T; Dolling, D; Rescigno, P; Figueiredo, I; Fauser, F; Wu, J; Rottenberg, JT; Shatkina, L; Ester, C; Luy, B; Puchta, H; Troppmair, J; Jung, N; Bräse, S; Strähle, U; Marto, JA; Nienhaus, GU; Al-Lazikani, B; Salvatella, X; de Bono, JS; Cato, AC; Brown, M (2017-08-10)
      Targeting the activation function-1 (AF-1) domain located in the N-terminus of the androgen receptor (AR) is an attractive therapeutic alternative to the current approaches to inhibit AR action in prostate cancer (PCa). ...